- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03660475
Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects
November 16, 2022 updated by: Sassani, Joseph S., MD, MHA
A Single-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects
The objective of this exploratory study is to determine the safety and efficacy of 0.002% Naltrexone Ophthalmic Solution, compared to placebo for the treatment of the signs and symptoms of dry eye in diabetic subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2, single-center, double-masked, randomized, placebo-controlled study to compare the safety and efficacy of Naltrexone Ophthalmic Solution, 0.002% to placebo for the treatment of the signs and symptoms of dry eye in diabetic subjects.
Subjects eligible to be randomized will receive one of the following treatments to be administered bilaterally BID for 29 days (from Visit 2 to Visit 5): Naltrexone Ophthalmic Solution, 0.002% or Placebo Ophthalmic Solution (Vehicle).
During a 10-day study run-in period (for the purpose of subject selection) prior to randomization, all subjects will receive Placebo Ophthalmic Solution (Vehicle) bilaterally BID.
Participants who terminate early during the application period will be asked to complete safety assessments (if the participants agree) prior to study exit.
Participants who are terminated early from the study will not be replaced.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Total Eye Care
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provide written informed consent;
- Have a diagnosis of type 1 or type 2 diabetes mellitus prior to Visit 1;
- Have a reported history of dry eye for at least 6 months prior to Visit 1;
- Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;
- Have a corneal fluorescein staining score of ≥ 2 in any region (inferior, superior, or central regions) in at least one eye at Visits 1 and 2 (must be the same eye at Visits 1 and 2);
Have at least one of the following at Visits 1 and 2:
- A total lissamine green conjunctival score of ≥ 2 in at least one eye, based on the sum of the temporal and nasal regions at Visits 1 and 2 (must be the same eye at Visits 1 and 2);
- Report an OSDI score ≥ 20 at Visits 1 and 2.
Exclusion Criteria:
- Have any clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
- Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
- Have concurrent neurotrophic keratopathy from a source other than diabetes (h/o HSV keratitis, h/o HZO with ocular manifestations, or CN VII palsy or other condition resulting in lagophthalmos);
- Have active diabetic foot ulcers;
- Have a corneal sensitivity score ≤ 1.5 cm as measured by Cochet-Bonnet at Visit 1;
- Report an OSDI score > 75 at Visits 1 and 2;
- Have worn contact lenses within 21 days of Visit 1 or anticipate using contact lenses during the study (no contact lens wear during study);
- Have used any eye drops within 2 hours of Visit 1;
- Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 24 months;
- Have used cyclosporine 0.05% or lifitigrast 5.0% ophthalmic solution within 45 days of Visit 1;
- Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within the last 12 months;
- Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;
- Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study);
- Have corrected visual acuity greater than or equal to logMAR +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in either eye at Visit 1;
- Have concurrent autoimmune disease causing dry eye (e.g., rheumatoid arthritis, Sjogren's, GVHD, Steven's Johnson, Grave's);
- Have Fuchs endothelial dystrophy;
- Have recurrent corneal erosion syndrome or anterior basement membrane dystrophy;
- Be a woman who is pregnant, nursing, or planning a pregnancy;
- Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 5 (or early termination visit) if of childbearing potential. Non-childbearing potential is defined as a woman who is permanently sterilized (i.e., has had a hysterectomy or bilateral tubal ligation), or is post-menopausal (without menses for 12 consecutive months);
- Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, they must agree to use adequate birth control as defined above for the remainder of the study;
- Have a known allergy and/or sensitivity to the test article or its components;
- Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
- Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;
- Be currently using any medication known to cause ocular drying that is not used on a stable dosing regimen for at least 30 days prior to Visit 1;
- Be unable or unwilling to follow instructions, including participation in all study assessments and visits.
- Be currently using a systemic opioid antagonist (e.g., Naltrexone or Naloxone) or have used a systemic opioid antagonist in the previous 90 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Naltrexone
Naltrexone Ophthalmic Solution 0.002%
|
naltrexone formulated as ophthalmic solution
|
Placebo Comparator: Placebo
Placebo Ophthalmic Solution
|
Placebo ophthalmic solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Ocular Surface Disease Index
Time Frame: Day 29
|
The OSDI is a 12-item questionnaire designed to provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning.
It is a scale of 0-4 for each of the 12 questions.
A minimum value would be "0" and a maximum value would be "48".
The higher the value the worse the outcome.
|
Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lissamine Green Staining
Time Frame: Day 29
|
Lissamine green staining; regions: inferior, superior, central, corneal sum, temporal, nasal, conjunctival sum, total eye will be measured using an ocular discomfort score on a scale of 0 (no staining) to 4 (confluent staining).
The total eye score is presented.
A minimum score would be "0" and a maximal score would be "8".
The higher the value the worse the outcome.
|
Day 29
|
Tear Film Break-up Time
Time Frame: Day 29
|
Tear film break-up time is the time taken for the first dry spot to appear on the cornea after a complete blink.
|
Day 29
|
Conjunctival Redness
Time Frame: Day 29
|
Conjunctival redness will be assessed and conjunctival pain will be assessed using a visual analog scale ranging from "0" (none: normal without vasodilation) to "5" (severe: broad ciliary and prominent, horizontal conjunctival vasodilation).
A minimal score would be "0" and a maximal score would be "10".
The higher the value the worse the outcome .
|
Day 29
|
Schirmer's Test
Time Frame: Day 29
|
Schirmer's Test (without anesthesia) ) involves placing a Schirmer test strip in the lower temporal lid margin of each eye such that the strip fits tightly.
Subjects will be instructed to close their eyes.
After 5 minutes have elapsed, the Schirmer strip will be removed.
The length of the moistened area will be recorded (mm) for each eye.
A normal reading is ≥10 mm wetting of the paper after 5 minutes.
Tear deficiency is <5 mm wetting of the paper after 5 minutes.
|
Day 29
|
Cochet-Bonnet Corneal Sensitivity Test
Time Frame: Day 29
|
After extending the Cochet-Bonnet corneal sensitivity device (containing a thin, retractable, nylon monofilament) up to 6 cm in length and pressing against the cornea, the monofilament is slowly retracted incrementally in 0.5 cm steps until the patient can feel its contact and the length is recorded.
The greater the length indicates increased sensation and the shorter the length indicates decreased sensation.
|
Day 29
|
Tear Osmolarity
Time Frame: Day 29
|
Normal tear osmolarity is defined as < 300 mOsm/L in both eyes and an inter-eye difference of < 8 mOsm/L.
Values greater than 300 mOsm/L are suggestive of dry eye.
|
Day 29
|
Matrix Metalloprotienase-9 (MMP-9) is a Marker of Inflammation.
Time Frame: Day 29
|
Levels of MMP-9 will be measured in each eye using InflammaDry at Visit 5.
The test will be recorded as either positive or negative.
Dry eye patients generally exhibit positive levels of MMP-9., so the number of subjects testing positive for MMP-9 at Day 29 will be recorded.
|
Day 29
|
Ocular Discomfort (Scale 1)
Time Frame: Day 29
|
Ocular discomfort scores will be subjectively graded by the subjects according to the following scale, rating each eye separately on a scale from 0-4.
A score of "0" represents no discomfort and a score of "4" represents constant discomfort.
A minimum score would be "0" and a maximum score would be "8".
The higher the value the worse the outcome.
|
Day 29
|
Ocular Discomfort (Scale 2)
Time Frame: Day 29
|
Subjects will rate the severity of each of the following symptoms, with regard to how both their eyes feel: overall ocular discomfort, burning, dryness, grittiness and stinging according to the following 6-point (0 to 5) scale where 0 = none and 5 = worst.
A minimum score would be "0" and a maximum score would be "10".
The higher the value the worse the outcome.
|
Day 29
|
Visual Analog Scale for Pain
Time Frame: Day 29
|
Standard scale assessing a patient's level of pain on a scale of 0-100.
The subject will be asked to rate each ocular symptom due to ocular dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort.
0% corresponds to "no discomfort" and 100% corresponds to "maximal discomfort".
The following parameters will be assessed: burning/stinging, itching, foreign body sensation, blurred vision, eye dryness, photophobia, and pain, with a total score for each eye reported.
A minimal score would be "0" and a maximum score would be "200".
The higher the value the worse the outcome.
|
Day 29
|
Fluorescein Staining
Time Frame: Day 29
|
The following regions of each eye will be assessed for fluorescein staining: inferior, superior, central, corneal sum, temporal, nasal, conjunctival sum, and a total eye score recorded.
A score of "0" represents no staining and a score of "4" represents confluent staining.
A minimum score would be "0" and a maximum score would be "8".
A higher values represent a worse outcome.
|
Day 29
|
Visual Acuity Measured by Assessing Average Change in LogMAR Units for Both Eyes at Day 29. LogMAR Units Range From 0-1.0, With the Higher the Number Indicating a Worsening in Vision.
Time Frame: Day 29
|
Mean change in visual acuity (LogMAR units 0-1.0) for both eyes at Day 29 was determined for each treatment arm and considered a measure of safety.
|
Day 29
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-related Adverse Events
Time Frame: Adverse events will be collected from first dose of study drug to 30 days after treatment discontinuation (Day 29 + 4 weeks).
|
An adverse event is defined as any untoward medical occurrence associated with the use of the investigational agent (or placebo) regardless of whether or not it is considered related to the investigational drug (or placebo).
|
Adverse events will be collected from first dose of study drug to 30 days after treatment discontinuation (Day 29 + 4 weeks).
|
Slit-lamp Biomicroscopy
Time Frame: Day 29
|
The binocular slit-lamp examination provides a stereoscopic magnified view of the eye structures in detail, enabling anatomical diagnoses to be made of the cornea, conjunctiva, anterior chamber, iris, lens and lid for both eyes.
The number of subjects in each treatment arm that have changes in the cornea, conjunctiva, anterior chamber, iris, lens and lid for both eyes at Day 29 will be reported.
|
Day 29
|
Intraocular Pressure
Time Frame: Day 29
|
Intraocular pressure is the fluid pressure inside the eye.
|
Day 29
|
Dilated Fundoscopy
Time Frame: Day 29
|
Dilated fundus examination is a diagnostic procedure that employs the use of mydriatic eye drops to dilate the pupil in order to obtain a better view of the fundus of the eye.
The number of subjects that demonstrate clinically significant abnormalities in the vitreous, choroid, macula, and optic nerve at Day 29 in either treatment arm will be reported.
|
Day 29
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eugene B McLaurin, M.D., Total Eye Care
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2018
Primary Completion (Actual)
November 1, 2018
Study Completion (Actual)
November 15, 2018
Study Registration Dates
First Submitted
July 18, 2018
First Submitted That Met QC Criteria
September 4, 2018
First Posted (Actual)
September 6, 2018
Study Record Updates
Last Update Posted (Actual)
December 2, 2022
Last Update Submitted That Met QC Criteria
November 16, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Eye Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Alcohol Deterrents
- Naltrexone
Other Study ID Numbers
- DDES001/18-110-0002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Disease
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Laboratorios Sophia S.A de C.V.Not yet recruitingOcular Surface Disease | Dry Eye Disease | Dry Eye Sensation
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
Fundación Oftalmológica Los AndesAlcon ResearchNot yet recruitingCataract | Dry Eye Syndrome | Dry Eye Disease | Phacoemulsification | Evaporative Dry Eye
-
Vienna Institute for Research in Ocular SurgeryTerminated
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
Clinical Trials on Naltrexone
-
San Diego State UniversityRecruitingPlacebo | NaltrexoneUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem DrinkingUnited States
-
Alkermes, Inc.Terminated
-
Alkermes, Inc.Completed
-
Alkermes, Inc.Completed
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...CompletedOpioid-Related Disorders | Heroin DependenceUnited States, Russian Federation
-
Centre for Addiction and Mental HealthUnknown
-
Drug Delivery Company, LLC DBA Akyso PharmaceuticalsNational Institute on Drug Abuse (NIDA); Laboratory Corporation of America; Cognitive...Not yet recruiting
-
Medical University of LublinRecruitingQuality of Life | Vulvodynia | NaltrexonePoland
-
State University of New York - Upstate Medical...CephalonCompletedAlcohol Dependence | Schizophrenia | Schizoaffective Disorders | Bipolar DisordersUnited States